Debt-to-equity of 4D Molecular Therapeutics, Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
4D Molecular Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • 4D Molecular Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 12%, a 63% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

4D Molecular Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 12% +4.5% +63% 30 Sep 2025
Q2 2025 10% +3.4% +49% 30 Jun 2025
Q1 2025 8.4% +0.72% +9.3% 31 Mar 2025
Q4 2024 7.2% -2.7% -27% 31 Dec 2024
Q3 2024 7% -3.4% -32% 30 Sep 2024
Q2 2024 6.8% -4.1% -37% 30 Jun 2024
Q1 2024 7.7% -4.1% -35% 31 Mar 2024
Q4 2023 9.9% -1.4% -13% 31 Dec 2023
Q3 2023 10% -0.34% -3.2% 30 Sep 2023
Q2 2023 11% +1% +10% 30 Jun 2023
Q1 2023 12% +3.1% +36% 31 Mar 2023
Q4 2022 11% +2.2% +25% 31 Dec 2022
Q3 2022 11% +1.4% +14% 30 Sep 2022
Q2 2022 9.9% 30 Jun 2022
Q1 2022 8.7% 31 Mar 2022
Q4 2021 9% 31 Dec 2021
Q3 2021 9.4% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.